Key result
Capecitabine use is linked to severe, reversible hepatic steatosis in a colon cancer patient.
Why the study?
There are no known case reports of hepatic steatosis caused by oral fluoropyrimidines such as capecitabine despite its increasing use.
Does capecitabine cause hepatic steatosis in patients with colon cancer?
Case Report (n=1)
No
Does capecitabine cause hepatic steatosis in patients with colon cancer?
Capecitabine use may be associated with reversible hepatic steatosis, highlighting the need for liver enzyme monitoring.
May warrant vigilance for hepatic steatosis with capecitabine; leaves open causality and generalizability beyond this case.
INTRODUCTION: There are no known case reports of hepatic steatosis caused by oral fluoropyrimidines such as capecitabine. With increasing use of capecitabine since its approval for the treatment of metastatic colon cancer in 2001, and more recently for adjuvant treatment of colon cancer and treatment of metastatic breast cancer, we can anticipate increased recognition of potential toxicities associated with this 5-fluorouracil derivative. CASE PRESENTATION: We report the case of a 74-year-old Armenian woman who received capecitabine as adjuvant treatment for colon cancer and subsequently developed abnormal liver biochemical tests and radiographic findings in keeping with hepatic steatosis. There was complete reversal of liver enzyme abnormalities with discontinuation of the drug and this patient represents a case of reversible liver injury due to capecitabine. CONCLUSION: In this original case report, capecitabine use was associated with hepatic steatosis. It is important for clinicians to recognize and monitor for this potential toxicity, which may be a cause of abnormal liver enzymes in this patient population.
No takes yet. Share an insight, caveat, or question.
Chin et al. (2010) conducted a case report in Stage III colon cancer (n=1). Capecitabine was evaluated on Development of hepatic steatosis. Capecitabine use was associated with the development of severe, reversible hepatic steatosis in a 74-year-old woman treated for colon cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: